Publication Name	World Journal of Clinical Cases
Manuscript ID	82502
Country	China

Received	2022-12-21 14:06
Peer-Review Started	2022-12-21 14:08
To Make the First Decision
Return for Revision	2023-01-20 00:42
Revised	2023-02-01 15:52
Second Decision	2023-03-20 03:15
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-03-20 09:19
Articles in Press	2023-03-20 09:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-03-23 10:33
Publish the Manuscript Online	2023-04-06 10:35

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Case Report
Article Title	Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Qian Zou, Rui-Lin Shen, Xiao Guo and Chen-Ye Tang
ORCID	Author(s) ORCID Number Qian Zou http://orcid.org/0000-0001-5646-8153 Chen-Ye Tang http://orcid.org/0000-0001-8640-197X
Funding Agency and Grant Number	Funding Agency Grant Number Jiaxing Science and Technology Foundation 2021AY30018
Corresponding Author	Chen-Ye Tang, Doctor, N/A, Department of Urology, The Second Affiliated Hospital of Jiaxing University, No. 1518 Huancheng Bei Lu, Nanhu District, Jiaxing 314001, Zhejiang Province, China. john99233@126.com
Key Words	Prostate cancer; Chemotherapy; Prostate-specific antigen; Rectal tumor; Androgen deprivation therapy; Case report
Core Tip	Chemotherapy is mainly used for castration-resistant prostate cancer (PC) (CRPC) and may also benefit patients with PC who have not progressed to CRPC. We describe a patient with high-risk locally advanced PC treated with laparoscopic radical prostatectomy plus short-term adjuvant hormonal therapy and rectal cancer treated with laparoscopic radical rectal resection plus adjuvant chemotherapy, and found that prostate-specific antigen declined after the capecitabine plus oxaliplatin chemotherapy.
Publish Date	2023-04-06 10:35
Citation	Zou Q, Shen RL, Guo X, Tang CY. Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report. World J Clin Cases 2023; 11(11): 2528-2534
URL	https://www.wjgnet.com/2307-8960/full/v11/i11/2528.htm
DOI	https://dx.doi.org/10.12998/wjcc.v11.i11.2528

Full Article (PDF)	WJCC-11-2528.pdf
Full Article (Word)	WJCC-11-2528.docx
CARE Checklist–2016	82502-CARE-Checklist–2016-revision.pdf
Manuscript File	82502_Auto_Edited-JLW.docx
Answering Reviewers	82502-Answering reviewers.pdf
Audio Core Tip	82502-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	82502-Conflict-of-interest statement.pdf
Copyright License Agreement	82502-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	82502-Grant application form(s).pdf
Signed Consent for Treatment Form(s) or Document(s)	82502-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	82502-Language certificate.pdf
Peer-review Report	82502-Peer-review(s).pdf
Scientific Misconduct Check	82502-Bing-Fan JR-2.png
Scientific Editor Work List	82502-Scientific editor work list.pdf